EUSA Pharma: Specialists in oncology, pain control and critical care

Welcome

Welcome to EUSA Pharma

EUSA Pharma is a specialty pharmaceutical company with a strong and growing portfolio of specialized hospital medicines focused on oncology, pain control and critical care, which it markets predominantly in Europe and the US (as the company’s name suggests).

EUSA Pharma has grown rapidly since its formation in 2006, and now incorporates Talisker Pharmaceuticals, which it acquired in July 2006, OPi, purchased in March 2007, the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc, acquired in August 2007, and Cytogen, which EUSA purchased in May 2008.

EUSA News

31st March 2009.
EUSA Pharma completes the European launch of Caphosol® for prevention and treatment of oral mucositis caused by cancer therapy

18th March 2009.
EUSA Pharma announces the appointment of David Cook to the newly-created role of Chief Financial Officer

22nd January 2009.
EUSA Chairman awarded “Outstanding Personal Contribution to UK Bioscience” by BIA

28th October 2008.
EUSA Pharma is pleased to announce the appointment of Nigel Pitchford, MA MBA PhD to the EUSA Pharma Board of Directors

9th May 2008.
EUSA Pharma announced today that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen’s shareholders at a special meeting on 8 May

1st May 2008
EUSA Pharma announces that it has divested its monoclonal antibody research business to the French company International Drug Development (IDD). therapeutic research program for acute lymphoblastic leukemia
Concurrently, EUSA divests its recombinant L-asparaginase to the Alizé Pharma Group

MORE NEWS>>

recovery

Last Updated: 9th June 2009

Back to home page

Legal | Privacy Policy